The influence of generator eluate in radiolabeling PSMA-11 kit with 68Ga

Bianca Franchesqueti Vivaldini; Elaine Bortoleti de Araújo

doi:10.15392/bjrs.v9i1A.1541

Authors

Bianca Franchesqueti Vivaldini Instituto de Pesquisas Energéticas e Nucleares
Elaine Bortoleti de Araújo Instituto de Pesquisas Energéticas e Nucleares

DOI:

https://doi.org/10.15392/bjrs.v9i1A.1541

Keywords:

prostate cancer, radiolabeling, radiopharmacy

Abstract

Gaining prominence in clinical practice, the ⁶⁸Ga, positron emitter radionuclide easily obtained by ⁶⁸Ge/⁶⁸Ga generator elution, has shown potential and excellent quality on radiolabeling of peptide for use in positron emission tomography (PET), in particular urea-based inhibitor peptides, directed to the prostate-specific membrane receptor (PSMA). Previous studies with the PSMA linked to the chelator HBED-CC (PSMA-11) radiolabeled with ⁶⁸Ga showed high contrast PET/CT images to evaluate recurrence and metastasis of prostate cancer, becoming an important imaging agent in the clinical routine. This work intended to evaluate the influence of the quality of the ⁶⁸Ge/⁶⁸Ga generator eluate in direct labelling of PSMA-11 with ⁶⁸Ga, assisting in the development of kit for prompt radiolabeling. It was evaluated the ⁶⁸GaCl₃ eluate from ⁶⁸Ge/⁶⁸Ga non-GMP generator (manufacturer A) and ⁶⁸Ge/⁶⁸Ga GMP generator (manufacturer B), both commercially available. To evaluate the influence of the ⁶⁸Ga eluate on radiochemical yield of the preparations, the radiochemical purity was determined by thin layer chromatography and HPLC. The radiolabeling with non-GMP generator eluate was made with and without preliminary purification of the 68 gallium chloride eluate, employing cationic purification columns. The results showed higher radiochemical yield with the ⁶⁸GaCl₃eluate from the ⁶⁸Ge/⁶⁸Ga GMP generator, obtaining the radiolabeled product more easily and speed to clinical practice, without preliminary purification, as opposed to the use of non-GMP ⁶⁸Ge/⁶⁸Ga generator which required preliminary purification of the ⁶⁸GaCl₃eluate to promote satisfactory radiochemical purity results.

Views: 103
PDF Downloads: 170

Downloads

Download data is not yet available.

Author Biographies

Bianca Franchesqueti Vivaldini, Instituto de Pesquisas Energéticas e Nucleares

Centro de Radiofarmácia

Elaine Bortoleti de Araújo, Instituto de Pesquisas Energéticas e Nucleares

Centro de Radiofarmácia

References

BRAY, F.; FERLAY, J.; SOERJOMATARAM, I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, v. 00, p. 1-31, 2018.

Estimativa 2018: Incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva, INCA, 2017.

PACKER, J.; MAITLAND, N. The molecular and cellular origin of human prostate cancer. Biochimica et Biophysica Acta 1863, p. 1238-1260, 2016.

AFSHAR-OROMIEH, A. et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging, v. 42, p. 197–209, 2015.

MIYAHIRA, A.; et al. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate, 2018, p. 1-15, 2018.

VELIKYAN, I. Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, Volume 4, p.47–80, 2013.

BANERJEE, S. R.; POMPER, M. G. Clinical applications of Gallium-68. Appl Radiat Isot., v. 76, p. 2–13, 2013.

Gallium (68Ga) PSMA 11 injection, European pharmacopoeia, 2018.